Brisbane biotech Implicit Bioscience has developed a business model unusual in Australia: it aims to return money to investors. [ + ]

Melbourne agbiotech Hexima has been making waves with its fungal and insect-resistance technology and a tasty deal with DuPont. [ + ]

Biota, CSL, Hexima, Alchemia, Mesoblast [ + ]

Mesoblast approved for Phase II trail for cervical spine fusion [ + ]

Prima BioMed applies for IND for CVac, raises cash [ + ]

Scientific equipment and consumables company Biolab has been aquired by Thermo Fisher Scientific.

With the discovery of a potentially key gene in the cell senescence process, Professor Jenny Gamble is looking at the role of senescence in vascular cells. [ + ]

“Walking seal” fossil sheds light on land-to-sea transition and pinniped evolution [ + ]

Biota, Circadian, Clinuvel, Cochlear, Pharmaxis, Diversa [ + ]

UK taxes rich, spends on tech investment fund [ + ]

Genetic Technologies, Circadian, Bionomics, Ambri, Hexima, LCT, Pharmaxis, Cellestis, AIC [ + ]

A study into two rare metabolic disorders shows that what may look like simple recessive or semi-dominant patterns of inheritance, may actually involve complex interactions with several other genes. [ + ]

Throat cancer added to list of targets for VDA, Celera developing proteomics-based lung cancer diagnostic [ + ]

Latest PwC BioForum report has unexpected good news, but fundamentals are unchanged [ + ]

Neuren, ChemGenex, Novogen, Biota, Alchemia, Impedimed, Sirtex [ + ]